PMID- 24552552
OWN - NLM
STAT- MEDLINE
DCOM- 20141121
LR  - 20211021
IS  - 2152-4998 (Electronic)
IS  - 2152-4971 (Print)
IS  - 2152-4971 (Linking)
VI  - 16
IP  - 2
DP  - 2014 Apr
TI  - Improving viability and transfection efficiency with human umbilical cord 
      wharton's jelly cells through use of a ROCK inhibitor.
PG  - 91-7
LID - 10.1089/cell.2013.0069 [doi]
AB  - Differentiating stem cells using gene delivery is a key strategy in tissue 
      engineering and regenerative medicine applications. Nonviral gene delivery 
      bypasses several safety concerns associated with viral gene delivery; however, 
      leading nonviral techniques, such as electroporation, subject cells to high 
      stress and can result in poor cell viabilities. Inhibition of Rho-associated 
      coiled-coil kinase (ROCK) has been shown to mitigate apoptotic mechanisms 
      associated with detachment and freezing of induced pluripotent stem cells and 
      embryonic stem cells; however, inhibiting ROCK in mesenchymal stromal cells 
      (MSCs) for improving gene delivery applications has not been reported previously. 
      In this study, we hypothesized that ROCK Inhibitor (RI) would improve cell 
      viability and gene expression in primary human umbilical cord mesenchymal stromal 
      cells (hUCMSCs) when transfected via Nucleofection. As hypothesized, the 
      pre-treatment and post-treatment of hUCMSCs transfected via nucleofection with 
      Y-27632-RI significantly improved survival rates of hUCMSCs and gene expression 
      as measured by green fluorescent protein intensity. This study provides the first 
      comparative look at the effect of Y-27632-RI on hUCMSCs that underwent 
      transfection via nucleofection and shows that using Y-27632-RI in concert with 
      nucleofection could greatly enhance the utility of differentiating and 
      reprogramming hUCMSCs for tissue engineering applications.
FAU - Mellott, Adam J
AU  - Mellott AJ
AD  - 1 Bioengineering Program, University of Kansas , Lawrence, KS, 66045.
FAU - Godsey, Megan E
AU  - Godsey ME
FAU - Shinogle, Heather E
AU  - Shinogle HE
FAU - Moore, David S
AU  - Moore DS
FAU - Forrest, M Laird
AU  - Forrest ML
FAU - Detamore, Michael S
AU  - Detamore MS
LA  - eng
GR  - R01 AR056347/AR/NIAMS NIH HHS/United States
GR  - R01 CA173292/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140219
PL  - United States
TA  - Cell Reprogram
JT  - Cellular reprogramming
JID - 101528176
RN  - 0 (Amides)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 138381-45-0 (Y 27632)
RN  - EC 2.7.11.1 (rho-Associated Kinases)
SB  - IM
MH  - Amides/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Mesenchymal Stem Cells/cytology/*metabolism
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Pyridines/*pharmacology
MH  - *Transfection
MH  - Umbilical Cord/cytology/*metabolism
MH  - rho-Associated Kinases/*antagonists & inhibitors
PMC - PMC3967373
EDAT- 2014/02/21 06:00
MHDA- 2014/12/15 06:00
PMCR- 2015/04/01
CRDT- 2014/02/21 06:00
PHST- 2014/02/21 06:00 [entrez]
PHST- 2014/02/21 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - 10.1089/cell.2013.0069 [pii]
AID - 10.1089/cell.2013.0069 [doi]
PST - ppublish
SO  - Cell Reprogram. 2014 Apr;16(2):91-7. doi: 10.1089/cell.2013.0069. Epub 2014 Feb 
      19.